U.S. Rep. Greg Steube representing Florida's 17th Congressional District | Official U.S. House headshot
U.S. Rep. Greg Steube representing Florida's 17th Congressional District | Official U.S. House headshot
Congressman Greg Steube, who represents Florida’s 17th congressional district, has recently used his social media platform to address issues ranging from child welfare to national trade and pharmaceutical policy.
On August 15, 2025, Steube announced a new legislative initiative in support of foster children. He wrote, "Every son and daughter of America deserves to grow up in a safe environment. Foster children are no exception. That is why I am introducing the bipartisan CARE for Children Act to expand options for foster youth and improve overall access to care in child welfare. Learn More: https://t.co/BooRDkmJo7"
The following day, on August 16, 2025, Steube commented on former President Donald Trump’s economic record: "President Trump has done a great job on trade. The mainstream media freaked out and predicted a recession. Instead, we have fair trade deals, lower taxes, and a more secure future for our country."
Continuing his praise of Trump administration policies, Steube posted on August 17, 2025: "President Trump is absolutely right that we need pharmaceutical companies to bring their manufacturing back to the United States. COVID-19 exposed the weaknesses in our supply chains. Thanks to the leadership of the Trump administration and Republicans, our economy is"
Steube’s remarks about child welfare legislation reflect ongoing bipartisan efforts in Congress aimed at improving conditions for foster youth across the United States. The introduction of acts such as CARE for Children comes amid broader national discussions regarding reforms in child welfare systems.
His statements on trade reference significant changes implemented during President Trump’s tenure between 2017 and 2021—particularly renegotiations of major agreements like NAFTA (replaced by USMCA) and various tariff policies targeting international competitors.
Regarding pharmaceutical manufacturing and supply chain vulnerabilities highlighted by COVID-19 disruptions beginning in early 2020, lawmakers from both parties have since advocated for increased domestic production capacity as part of broader pandemic preparedness strategies.